Participated · Seed · Sep 2024

Cercle’s core product is the Cercle Biomedical Graph™, an AI-driven platform that ingests and transforms raw, de-identified women’s healthcare data into high-quality, real-time insights. The Graph acts as a mediator between patient records and LLMs, anonymizes data, and is HIPAA- and GDPR-compliant. Since its November 2023 introduction the platform has been used by US Fertility, Boston IVF, and Eurofins Genoma and has captured and analyzed more than one billion anonymized data points. Cercle will use the seed funding to expand beyond the fertility market, broaden its global footprint, and advance its LLM capabilities and product engineering. The company aims to serve providers, payers, and pharma across reproductive health, menopause, women’s oncology, and rare diseases that disproportionately affect women. The company notes the Graph has not been evaluated by the FDA and is not classified as a medical device.

Participated · Seed · Sep 2024

Cercle’s core product is the Cercle Biomedical Graph™, a platform that ingests and transforms de-identified, unstructured women’s healthcare data into real-time, high-quality insights. The platform acts as a mediator between patient records and LLMs, anonymizing data and ensuring HIPAA and GDPR compliance while removing personal information. Since its November 2023 introduction, the Graph has captured and analyzed more than one billion anonymized patient data points and is used by partners including US Fertility, Boston IVF, and Eurofins Genoma. Cercle says its technology delivers insights at scale and speed without AI hallucinations, improving clinical workflows and business efficiency. The company plans to widen its application beyond the fertility market, expand its global footprint, and advance its LLM offerings. Management emphasizes product and engineering development to connect LLMs to high-quality women’s-health data and deliver secure, accurate, real-time answers for stakeholders. The company is privately held and recently closed a seed financing to support these efforts. Cercle’s platform has not been evaluated by the FDA and is not classified as a medical device.

Participated · Equity · Jul 2020

Made of Genes uses artificial intelligence, data science and systems biology to integrate biomarkers such as blood tests and DNA to deliver personalized health and wellbeing recommendations. The company originated as a spin-off of Genomcore and is staffed by around thirty healthcare professionals, biologists and engineers. It is expanding its Made of Genes ONE study to combine blood and DNA analyses with external athlete data — body parameters and biosensor metrics like sleep quality, muscle loads and injury records — for services to FC Barcelona. Made of Genes and Barça Innovation Hub plan to co-create pioneering AI algorithms for high‑performance athletes that explicitly incorporate a gender perspective to address the needs of female athletes. The platform aims to optimize performance, personalize training and recovery, predict injury risk and complement teams' guidance on nutrition and emotional wellbeing. Financially, the company announced investment from Barça Innovation Hub and recently closed a €2.4M funding round led by FCV Equity with participation from Scale Lab Andorra, Break Off Capital and Capital Cell. Made of Genes (the personalized-health brand of Genomcore S.L.) offers integrated health studies that combine genetic, serological (including IgG antibody tests) and biochemical/metabolic markers to deliver a comprehensive view of an individual’s health. The company has positioned its services to go beyond static genetic reports by adding a dynamic assessment of current health status and comorbidity risk, including a COVID-19–focused product called #REACTIVATE. #REACTIVATE is marketed as an affordable test (under €100) that identifies past infection, antibody response, and risk of severe respiratory complications. The newly closed financing will be used to scale the company’s VITAL and HEALTH service lines and to improve go-to-market execution. Made of Genes highlights data custody and reuse practices (including Blockchain-based privacy and consent management) as part of its innovation profile. The company was founded in January 2015 and has received recognition such as MIT Technology Review’s Innovators Under 35 and other international awards. Made of Genes operates a marketplace that sequences clients' genes, digitizes their genomes and hosts them in the cloud so customers can grant access to partnered healthcare professionals. The service monetizes via commissions when a client pays a professional to analyze their genome. The company was founded by Dr. Óscar Flores and consultant Miquel Bru and has secured commitments from 10 healthcare companies and integration with 150 disease‑detection apps. Made of Genes plans to generate €50,000 in revenue in its first year and expected to grow to 20 employees by 2017. The startup is based in Barcelona.

Participated · Equity · Jun 2017

Babyscripts offers a mobile clinical solution for remote monitoring in pregnancy, combining a mobile app with internet-connected devices, digital education, and customized risk-specific experiences. The platform enables providers and payers to manage patients via risk-based care modules, remote monitoring, and automated care elements. Babyscripts reports managing more than 200K unique pregnancies across 30 states and says its tools can allow providers to manage up to 90% of pregnancies virtually. The solution is delivered via a joint deployment model that incorporates payers sponsoring platform use at participating sites to identify and triage member risk and improve care coordination. The company emphasizes targeting and reducing systemic racial and ethnic inequities in maternal and infant outcomes. Babyscripts intends to use the new funding to accelerate rollout of its Virtual Maternity Care solution across U.S. providers and to develop models specifically designed for payers; the company has raised $37M to date. Babyscripts offers a virtual maternity care platform that pairs medical-device kits (blood pressure, weight, captured blood sugars) with a mobile app to monitor and alert clinicians to maternal health issues. The platform can automate roughly 40%–50% of prenatal care and has been shown to accelerate diagnoses (for example, preeclampsia detected 13 days faster than standard care at a site). Babyscripts is used by 75 health systems across 32 states and monitors about 250,000 women annually; more than 70% of its patients are on Medicaid. The company expanded product lines from a single device to multiple targeted kits and recently launched a mental health product while developing a substance use disorder experience. Babyscripts has formed partnerships with public health departments, managed Medicaid plans and providers to enable local payment and broader deployment. The company grew enrollments 10x during the pandemic and has 45 employees, with plans to double headcount in the next 12–18 months to support product, payer growth, clinical expertise, implementation and customer success. Babyscripts builds a clinically validated virtual care platform that allows OBGYNs to deliver a new model of prenatal and postpartum care using internet-connected devices for remote monitoring. The platform offers risk-specific experiences and the company says it can allow providers to manage up to 90% of pregnancies virtually. Babyscripts has spent six years developing what it describes as the most-implemented mobile clinical solution for remote monitoring in pregnancy and was named to CB Insights' 2020 Digital Health 150. The company emphasizes partnering with physicians and health systems to guide product development and improve maternal outcomes. Its stated mission is to eliminate maternal mortality and expand access to care. Recent health-system partnerships are intended to align Babyscripts' roadmap with customer needs and support scaling of its virtual maternity care solutions. Babyscripts offers a clinically-validated virtual care obstetrics platform that uses internet-connected devices for remote monitoring to support prenatal and postpartum care. The core product delivers risk-specific experiences to allow OBGYNs to manage a large portion of pregnancies remotely. The system is designed to detect risk more quickly and automate elements of care, enabling providers to manage up to 90% of pregnancies virtually. Led by CEO and co-founder Anish Sebastian, the company has spent the last four years building this platform. Babyscripts recently acquired iBirth, expanding its offering to include a provider-delivered, co-branded pregnancy app and a more holistic pregnancy and postpartum program. Financially, Babyscripts raised $500K from Inova Health System, which will support deployment of the platform. Babyscripts develops a mobile app and remote-monitoring devices that track blood pressure and weight and deliver neonatal care information to expecting mothers. The company works with hospitals and healthcare providers to distribute its devices and software, creating a channel between patients and OBGYNs throughout pregnancy. Using remote monitoring, Babyscripts says it can tailor treatments to risk profiles and enable providers to manage up to 90% of pregnancies virtually. The platform is already being used to monitor 160,000 pregnancies across 20 states, and the company reports average patient engagement of six app or monitoring interactions per week. Leadership says the company will use funding to continue acquiring market share and build additional products for pregnancy patients, including postpartum and early-stage pediatric services through expanded offerings.

Participated · Seed · Jul 2015

Medtep develops a technology solution focused on monitoring the prevention and treatment of diseases. Its platform lets users provide data and integrates that information with medical protocols for pathologies and treatments. The company was founded in Barcelona in 2011 by Jabob Suñol and Pablo Pantaleoni and initially raised €50,000 from Enisa and €150,000 from business angels. After a $2 million first round led by Stella Maris Partners, Medtep moved its legal and commercial headquarters to Silicon Valley and opened a delegation in Mexico. Barcelona continues to host a team of more than 25 people dedicated to product development and innovation. Medtep reported $350,000 in revenue in 2014, expected to double that figure in 2015, and aims to surpass $10 million within three years.